Floatz logo

Ceralasertib

Advanced or Metastatic NSCLC

Mario Negri Institute for Pharmacological ResearchPhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

1205 Active assets in the Advanced or Metastatic NSCLC cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Ceralasertib is also rated in:

Advanced Solid TumoursDormant
BB
Indicative ·
64 / 100
View asset →
breast cancerDormant
B
Indicative ·
60 / 100
View asset →
breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →